
    
      A decision was made to terminate the B1701002 study so that emerging data from the study and
      from a preclinical study in rats could be further examined and incorporated into a new study
      design and protocol.

      This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to
      Biogen.
    
  